EA200870389A1 - Стирилпиридиновые производные и их применение для связывания и визуализации амилоидных бляшек - Google Patents

Стирилпиридиновые производные и их применение для связывания и визуализации амилоидных бляшек

Info

Publication number
EA200870389A1
EA200870389A1 EA200870389A EA200870389A EA200870389A1 EA 200870389 A1 EA200870389 A1 EA 200870389A1 EA 200870389 A EA200870389 A EA 200870389A EA 200870389 A EA200870389 A EA 200870389A EA 200870389 A1 EA200870389 A1 EA 200870389A1
Authority
EA
Eurasian Patent Office
Prior art keywords
visualization
styrlypyridine
derivatives
binding
application
Prior art date
Application number
EA200870389A
Other languages
English (en)
Other versions
EA017898B1 (ru
Inventor
Ханк Ф. Кунг
Мей-Пинг Кунг
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA200870389A1 publication Critical patent/EA200870389A1/ru
Publication of EA017898B1 publication Critical patent/EA017898B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к способу визуализации амилоидных отложений и к стирилпиридинам и способам получения стирилпиридинов, меченных радиоактивными изотопами, применимых при визуализации амилоидных отложений. Данное изобретение также относится к соединениям и способам получения соединений для ингибирования агрегации амилоидных белков, при которой образуются амилоидные отложения, и к способу доставки лечебного средства к амилоидным отложениям.
EA200870389A 2006-03-30 2007-03-26 Стирилпиридиновые производные и их применение для связывания и визуализации амилоидных бляшек EA017898B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
PCT/US2007/007400 WO2007126733A2 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (2)

Publication Number Publication Date
EA200870389A1 true EA200870389A1 (ru) 2009-04-28
EA017898B1 EA017898B1 (ru) 2013-04-30

Family

ID=38326579

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870389A EA017898B1 (ru) 2006-03-30 2007-03-26 Стирилпиридиновые производные и их применение для связывания и визуализации амилоидных бляшек

Country Status (34)

Country Link
US (3) US7687052B2 (ru)
EP (3) EP2363391A1 (ru)
JP (1) JP5290954B2 (ru)
KR (1) KR101376807B1 (ru)
CN (1) CN101522624B (ru)
AT (1) ATE539060T1 (ru)
AU (1) AU2007243712B2 (ru)
BR (1) BRPI0710225B1 (ru)
CA (1) CA2644530C (ru)
CR (1) CR10329A (ru)
CY (3) CY1113048T1 (ru)
DK (2) DK2363392T3 (ru)
EA (1) EA017898B1 (ru)
EC (1) ECSP088783A (ru)
ES (2) ES2628882T3 (ru)
FR (1) FR13C0034I2 (ru)
GT (1) GT200800201A (ru)
HR (2) HRP20120135T1 (ru)
HU (2) HUE032660T2 (ru)
IL (1) IL193567A (ru)
LT (1) LT2363392T (ru)
LU (1) LU92232I2 (ru)
MX (1) MX2008012527A (ru)
NO (2) NO342090B1 (ru)
NZ (1) NZ570887A (ru)
PL (2) PL2363392T3 (ru)
PT (2) PT1999109E (ru)
RS (2) RS56171B1 (ru)
SG (1) SG173338A1 (ru)
SI (2) SI1999109T1 (ru)
TW (1) TWI399366B (ru)
UA (1) UA97802C2 (ru)
WO (1) WO2007126733A2 (ru)
ZA (1) ZA200807955B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007243712B2 (en) * 2006-03-30 2013-01-10 The Trustees Of The University Of Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
JP5322180B2 (ja) * 2007-07-04 2013-10-23 国立大学法人東北大学 フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
US8557222B2 (en) 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
UA105914C2 (ru) * 2008-12-31 2014-07-10 Евід Рейдіофармасьютікалз, Інк. Синтез стирилпиридина, меченного радиоизотопом 18f, из тозилатного прекурсора и стабильная фармацевтическая композиция на его основе
CA2767475A1 (en) * 2009-07-10 2011-01-13 Bayer Pharma Aktiengesellschaft Usage of low to medium-pressure liquid chromatography for the purification of radiotracers
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
EA022447B1 (ru) * 2009-12-23 2016-01-29 Пирамаль Имэджинг Са Композиции, приемлемые для рет-визуализации при помощи гидрофобных рет-агентов
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
MX2012014116A (es) * 2010-06-04 2013-08-08 Piramal Imaging Sa Metodo para la produccion de ligandos beta amiloide marcados con 18f.
SG185785A1 (en) * 2010-06-04 2013-01-30 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligand
ES2642086T5 (es) 2010-06-04 2020-04-13 Life Molecular Imaging Sa Procedimiento para la producción de ligandos de beta amiloide marcados con F-18
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
EP2627361B1 (en) * 2010-10-12 2017-09-20 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
CA3058702C (en) 2011-04-21 2023-11-07 Massoud Akhtari Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
MX2014004274A (es) 2011-10-19 2014-07-09 Piramal Imaging Sa METODO MEJORADO PARA LA PRODUCCION DE LIGANDOS Aß MARCADOS CON F-18.
SG10201608370TA (en) 2012-04-10 2016-11-29 Lantheus Medical Imaging Inc Radiopharmaceutical synthesis methods
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
HUE053939T2 (hu) 2014-05-13 2021-08-30 Hoffmann La Roche Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk
AU2016308189B2 (en) 2015-08-18 2021-03-11 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (en) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Styryl compounds and use thereof as medicine
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
WO2001070667A1 (fr) * 2000-03-22 2001-09-27 Bf Research Institute, Inc. Sonde de diagnostic par image, a base d'azobenzene substitue ou d'un analogue de celui-ci, pour les maladies imputables a l'accumulation d'amyloide et composition pour le diagnostic par image le contenant
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
DK1432453T3 (da) * 2001-08-27 2013-11-18 Univ Pennsylvania Stilbenderivater og anvendelse heraf til binding og billeddannelse af amyloid-plaques
CN1672283A (zh) 2002-06-06 2005-09-21 宾夕法尼亚州大学理事会 陶瓷阳极及其制造方法
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
WO2006078384A2 (en) * 2004-12-17 2006-07-27 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use
DK2213652T3 (en) * 2004-12-17 2015-01-26 Univ Pennsylvania Stilbene AND USE THEREOF FOR BINDING AND IMAGING OF amyloid plaques
AU2006261917A1 (en) * 2005-06-24 2007-01-04 The Trustees Of The University Of Pennsylvania Radiolabeled-pegylation of ligands for use as imaging agents
AU2007243712B2 (en) * 2006-03-30 2013-01-10 The Trustees Of The University Of Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
US20080253967A1 (en) * 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
IL193567A (en) 2014-03-31
RS56171B1 (sr) 2017-11-30
HUS1300028I1 (hu) 2017-08-28
RS52222B (en) 2012-10-31
US20080038195A1 (en) 2008-02-14
AU2007243712A1 (en) 2007-11-08
SI1999109T1 (sl) 2012-04-30
US20090123369A1 (en) 2009-05-14
MX2008012527A (es) 2008-10-14
HRP20120135T1 (hr) 2012-03-31
WO2007126733A3 (en) 2008-03-06
ZA200807955B (en) 2012-11-28
KR101376807B1 (ko) 2014-03-20
UA97802C2 (ru) 2012-03-26
CY2013024I2 (el) 2015-11-04
BRPI0710225B1 (pt) 2021-07-13
ECSP088783A (es) 2008-10-31
CY2013024I1 (el) 2015-11-04
NO342090B1 (no) 2018-03-19
NO20084590L (no) 2008-12-29
SG173338A1 (en) 2011-08-29
KR20080106564A (ko) 2008-12-08
HUE032660T2 (en) 2017-10-30
TWI399366B (zh) 2013-06-21
FR13C0034I2 (fr) 2014-03-07
DK2363392T3 (en) 2017-07-03
EP2363391A1 (en) 2011-09-07
BRPI0710225A2 (pt) 2011-08-02
IL193567A0 (en) 2009-05-04
CA2644530C (en) 2015-05-19
GT200800201A (es) 2009-08-20
HRP20170857T1 (hr) 2017-12-01
EP1999109B1 (en) 2011-12-28
EP1999109A2 (en) 2008-12-10
JP2009532349A (ja) 2009-09-10
US8506929B2 (en) 2013-08-13
SI2363392T1 (sl) 2017-09-29
US8840866B2 (en) 2014-09-23
CA2644530A1 (en) 2007-11-08
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
US7687052B2 (en) 2010-03-30
EP2363392B1 (en) 2017-05-03
US20130129624A1 (en) 2013-05-23
FR13C0034I1 (ru) 2013-08-09
PL2363392T3 (pl) 2017-10-31
DK1999109T3 (da) 2012-04-02
LU92232I2 (fr) 2013-08-26
LU92232I9 (ru) 2019-01-15
TW200838852A (en) 2008-10-01
NZ570887A (en) 2011-05-27
EA017898B1 (ru) 2013-04-30
CR10329A (es) 2008-10-29
ES2628882T3 (es) 2017-08-04
PT1999109E (pt) 2012-03-16
NO2018030I1 (no) 2018-09-11
LT2363392T (lt) 2017-07-25
CY1113048T1 (el) 2015-11-04
EP2363392A1 (en) 2011-09-07
CN101522624B (zh) 2013-11-06
WO2007126733A2 (en) 2007-11-08
ATE539060T1 (de) 2012-01-15
ES2378785T3 (es) 2012-04-17
CN101522624A (zh) 2009-09-02
AU2007243712B2 (en) 2013-01-10
CY1119048T1 (el) 2018-01-10
JP5290954B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
EA200870389A1 (ru) Стирилпиридиновые производные и их применение для связывания и визуализации амилоидных бляшек
EA200701299A1 (ru) Производные стильбена и их применение для связывания и визуализации амилоидных бляшек
CY1122278T1 (el) Αντι il-36r αντισωματα
BR112015014751A2 (pt) anticorpos anti-tau humanos
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
PH12014502406A1 (en) Anti-il-23p19 antibodies
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
EA200970551A1 (ru) Производные ацетилена и их применение для связывания и визуализации бляшек амилоида
EA201400237A1 (ru) Фолатные конъюгаты альбуминсвязывающих частиц
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
EA200970816A1 (ru) Новая лекарственная форма
UA91996C2 (ru) Производные стильбена и их применение для связывания и визуализации амилоидных бляшек
PL399592A1 (pl) Kompozycja farmaceutyczna do stosowania miejscowego zawierajaca acyklowir oraz sposób jej wytwarzania

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KZ RU